Accelerated Approval of New TKI Use in CML Sparks Questions
US regulators’ use of a speedy clearance pathway for a new frontline indication for asciminib for chronic myeloid leukemia (CML) has raised questions due to the number of medications already available for this condition. In October, the US Food and Drug Administration (FDA) granted accelerated approval to asciminib (Scemblix…
US regulators’ use of a speedy clearance pathway for a new frontline indication for asciminib for chronic myeloid leukemia (CML) has raised questions due to the number of medications already available for this condition. In October, the US Food and Drug Administration (FDA) granted accelerated approval to asciminib (Scemblix…
Read More
About Author
